New findings from the COAST trial led by researchers at Yale Cancer Center show that adding oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC). The findings were presented this month at the annual meeting of the European Society for Medical Oncology (ESMO).
Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and a member of LCRF’s Scientific Advisory Board, is lead author of the study.